New Molex Campus in Poland to Support Medical Device Delivery
16 Nov 2023
Phillips-Medisize, a Molex company, will be able to provide its pharmaceutical and medtech customers with new capabilities and support through an expanded European footprint.
Molex has opened a new campus in Katowice, Poland. The facility's initial 23,000 square-meter manufacturing space is intended to serve as a strategic central location to help facilitate timely delivery of advanced medical devices for Phillips-Medisize, as well as electric vehicle and electrification solutions for Molex customers. Future expansion of up to 85,000 square meters is built into the company's growth plans for the facility.
So far, Molex has invested $110 million in these facilities that will initially support Phillips-Medisize with production of pharmaceutical, medical and diagnostic devices. The site capabilities will include advanced medical device assembly, packaging, drug handling, and injection molding.
Image courtesy of Molex
Preview
Source: mddionline
The Katowice campus will complement Phillips-Medisize's existing operations at six European manufacturing sites in Ireland, Denmark, Czech Republic, and two locations in Kontiolahti, Finland.
The large pool of skilled manufacturing and engineering resources in the Katowice area was a major factor influencing Molex's selection of the site location, the company noted. At planned capacity, the first facilities within the campus will employ about 350 employees, including highly skilled production operators, design engineers, and quality specialists.
Combining high technology expertise and skilled labor means that both Phillips-Medisize medical customers and Molex automotive and electrification customers now have access to the company's expert capabilities, high-quality services and support in a location that enables speed-to-market and superior quality in product delivery.
The campus will be the first site for both Molex and Phillips-Medisize to hold a LEED Gold certification. ISO 13485 certification is pending construction completion, with additional certifications and registrations to follow, offering more localized value to those customers who require this exacting manufacturing quality.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.